CN102399718A - Strain of Lactobacillus paracasei GMNL-133 and composition for improving atopic dermatitis or other allergic diseases and purpose thereof - Google Patents
Strain of Lactobacillus paracasei GMNL-133 and composition for improving atopic dermatitis or other allergic diseases and purpose thereof Download PDFInfo
- Publication number
- CN102399718A CN102399718A CN2011103194077A CN201110319407A CN102399718A CN 102399718 A CN102399718 A CN 102399718A CN 2011103194077 A CN2011103194077 A CN 2011103194077A CN 201110319407 A CN201110319407 A CN 201110319407A CN 102399718 A CN102399718 A CN 102399718A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus
- gmnl
- strain
- lactobacillus johnsonii
- atopic dermatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to a separated strain of Lactobacillus paracasei GMNL-133, which is preserved in China Center for Type Culture Collection (CCTCC), and the preservation number is CCTCC M 2011331. The strain of Lactobacillus paracasei GMNL-133 is used for producing compositions for treating atopic dermatitis or other allergic diseases. In addition, the invention relates to a composition including the strain of Lactobacillus paracasei GMNL-133, and the content of the strain of Lactobacillus paracasei GMNL-133 is enough to effectively treat atopic dermatitis or other allergic diseases.
Description
Technical field
The present invention relates to a kind of lactobacillus strains and uses thereof, particularly relate to a kind of secondary lactobacillus johnsonii strain and comprise its compsn and the purposes that are used to improve anaphylactic disease.
Background technology
Allergy is a kind of acquired to the untoward reaction in the normal innoxious substance generation immunity.The symptom that anaphylaxis causes has itch, cough, asthma, sneeze, tearful eyes, inflammation and tired etc.It is believed that anaphylaxis comprises early stage specificity immunoreation and inflammatory reaction in late period.According to reports, sensibiligen (like pollen and dirt mite) is through stimulating the early stage anaphylaxis of high affinity immune globulin E (IgE) intermediary.Particularly, when mastocyte and basophilic granulocyte receive sensibiligen and stimulate, can release tissue amine and cytohormone.Cytohormone is subsequently through assembling the anaphylaxis in late period of inflammatory cells intermediary.Also there is report to point out eosinophilic granulocyte, scavenger cell, lymphocyte, neutrophilic granulocyte and hematoblastic compiling to open virulent inflammatory reaction circulation in late period.The anaphylaxis in late period strengthens initial immunoreation, discharges more inflammatory cells then impel.
Existing at present multiple therapy is used to treat allergic symptom, comprises and uses anti-allergic agent and I4EA H-receptor antagonist (antihistaminic).Antihistaminic can alleviate by I4EA and acts on the symptoms such as hyperemia, itch and swelling that destination organization causes, and can prevent or relax many symptoms that is caused by the mastocyte degranulation.But, simultaneously report is also arranged, point out that antihistaminic can produce some spinoffs, for example alertness reduction, slow in reacting and drowsiness.
Atopic dermatitis is the modal a kind of anaphylaxy of children.The traditional method of treatment atopic dermatitis is the topical steroids therapy, but the atopic dermatitis symptom is difficult to eradicate in fact, and often recurrence after the drug withdrawal.Moreover the life-time service Steroid treatment is easy to generate spinoff, and for example skin atrophy attenuation, skin pigment change, become mildewed, grow acne etc.Therefore, few side effects and safe, medicament that can relieved use becomes patient and desired clinically.
Probiotic bacterium is helped HUMAN HEALTH by medical circle and scientific circles' identification in recent years, and has no side effect.Food and Agricultural Organization of the United Nations (FAO) and The World Health Organization (WHO) are defined as probiotic bacterium (probiotics): the mikrobe that lives, when it is the proper amt administration, can give host's one health advantages (health benefit).The mikrobe that can be used as the probiotic bacterium use at present has numerous species, for example lactobacillus genus (Lactobacillus), double fork lever Pseudomonas (Bifidobacterium), lactococcus genus (Lactococcus), enterococcus spp (Enterococcus), Saccharomycodes (yeasts), streptococcus (Streptococcus) or the like.
Lactobacillus genus is the gram-positive facultative anaerobe of a group, is prevalent in human gi tract and intravaginal, can fermenting carbohydrate and be main metabolites with lactic acid.There are many research and clinical trial to confirm to have between lactobacillus spp and the health important dependency all successively.At present, the found effect of lactobacillus spp comprises: (1) is promoted the bacterium of intestinal microbiota and is balanced each other; (2) prevention diarrhoea; (3) danger of reduction colorectal carcinoma; (4) normal development and the function of stimulating gastrointestinal epithelium mucous membrane system; (5) produce various VITAMINss and nutrient substance; And (6) prevention and treatment vaginitis.
Summary of the invention
One side of the present invention is to provide a kind of separated secondary lactobacillus johnsonii strain GMNL-133; It is preserved in Chinese typical culture collection center (China Center for Type Culture Collection; CCTCC), deposit number is CCTCC M 2011331.
Another aspect of the present invention is to provide the purposes of a kind of secondary lactobacillus johnsonii strain GMNL-133, and it is used to make the compsn of treatment atopic dermatitis.
According to above-mentioned aspect of the present invention, a kind of compsn that is used to treat atopic dermatitis is proposed, comprise secondary lactobacillus johnsonii strain GMNL-133, and content that should pair lactobacillus johnsonii strain GMNL-133 can effectively improve atopic dermatitis.
Another aspect of the present invention is to provide the purposes of a kind of secondary lactobacillus johnsonii strain GMNL-133, and it is used to make the compsn of treatment anaphylactic disease.
According to above-mentioned aspect of the present invention, a kind of compsn that is used to treat anaphylactic disease is proposed, comprise secondary lactobacillus johnsonii strain GMNL-133, and the content of secondary lactobacillus johnsonii strain GMNL-133 can effectively improve anaphylactic disease.
According to one embodiment of the invention, secondary lactobacillus johnsonii strain GMNL-133 can be viable bacteria or the heat treated dead bacterium of process.And the compsn of treatment atopic dermatitis or anaphylactic disease can be medical composition or food compsns.
According to another embodiment of the present invention; The compsn of treatment atopic dermatitis or anaphylactic disease can further comprise at least a other bacterial strain, and this other bacterial strain is selected from the group that is made up of the arbitrary combination of lactobacillus acidophilus (Lactobacillus acidophilus), lactobacillus plantarum (Lactobacillus plantarum), bifidus longum bb (Bifidobacterium longum), fermentation lactobacillus (Lactobacillus fermentum), bulgaricus ccm (Lactobacillus bulgaricus), thermophilus streptococcus (Streptococcus thermophilus), cheese lactobacillus spp (Lactobacillus cremors), rhamnose lactic acid bacteria (Lactobacillus rhamnosus), lactobacillus reuteri (Lactobacillus reuteri) and above-mentioned bacterium.
Brief Description Of Drawings
Fig. 1 is the aspect graph of strain isolated GMNL-133 in microscopically.
Fig. 2 is the RAPD electrophorogram of secondary lactobacillus johnsonii strain in secondary lactobacillus johnsonii strain GMNL-133 and other commercially available prod.
Fig. 3 stimulates the column diagram of the IFN-γ expression amount of mouse spleen cell generation respectively for secondary lactobacillus johnsonii strain in secondary lactobacillus johnsonii strain GMNL-133 and other commercially available prod.
Fig. 4 A to 4B is respectively in the sensitized mice pattern experiment, and IgE and IgG2a expression amount are with the standardized column diagram of the expression amount of placebo in serum of each group, and the * mark representes to compare with placebo the significant difference (p＜0.05) that has on the statistics.
Fig. 5 A to 5D is respectively in the experiment of sensitized mice pattern; TGF-β, IFN-γ, IL-10 and IL-17 expression amount in spleen cell nutrient solution of each group are with the standardized column diagram of the expression amount of placebo, and the * mark representes to compare with placebo the significant difference (p＜0.05) that has on the statistics.
Fig. 6 A is that each organizes the column diagram of mouse right ear thickness results in the atopic dermatitis mouse pattern experiment, and the * mark representes to compare with placebo the significant difference (p＜0.05) that has on the statistics.
Fig. 6 B to 6C is respectively in the experiment of atopic dermatitis mouse pattern; Each organizes IgE and IgG1 expression amount in the mice serum with the standardized column diagram of the expression amount of placebo, and the * mark representes to compare with placebo the significant difference (p＜0.05) that has on the statistics.
Fig. 6 D is in the atopic dermatitis mouse pattern experiment, and each organizes the expression amount of the TNF-α in the mouse ear tissue with the standardized column diagram of the expression amount of placebo, and the * mark representes to compare with placebo the significant difference (p＜0.05) that has on the statistics.
Embodiment
There is report to point out to treat allergy at present through regulating cytohormone.Wherein, gamma-interferon (IFN-γ) can suppress the over-expresses of the cytohormone of II type helper cell (Th2), particularly suppresses the secretion of white plain-4 (IL-4) that is situated between, and then reduces the propagation of bone-marrow-derived lymphocyte.In addition, IFN-γ also can stimulate the immunoreation of I type helper cell (Th1), suppresses the synthetic of IgE.Therefore, believe that IFN-γ is effectively irritated for treatment.
Therefore, the present invention provides the lactobacillus paracasei strain GMNL-133 of a novelty, and said bacterial strain GMNL-133 tool stimulates the ability of the spleen cell secretion of gamma-IFN of mouse, can be used for making the compsn of treatment anaphylactic disease.Lactobacillus paracasei strain GMNL-133 is preserved in Chinese typical culture collection center (CCTCC) (China, Wuhan, Wuhan University, 430072) according to the regulation of budapest treaty on September 26th, 2011, and preserving number is CCTCCM2011331.This lactobacillus paracasei strain GMNL-133 (CCTCC M 2011331) can comprise other compositions such as at least a pharmaceutically acceptable vehicle and/or thinner; For example glucose, maltodextrin, dry milk prod, Nutriflora P, Magnesium Stearate, yogurt spices, other is difficult to isolating composition or above-mentioned arbitrary combination, and this other composition and compound method are known by technician under the technical field of the present invention.In addition, the consumption of lactobacillus paracasei strain GMNL-133 (CCTCC M 2011331) can be every kilogram about 1 * 106 to about 1 * 1011 colony-forming unit (CFU/g).
So-called " anaphylactic disease " is meant the allergy that atopic dermatitis, allergic rhinitis and asthma and food that some are specific and sting cause.These diseases can cause the inflammatory response of certain degree, cause the chronic inflammation of skin, mucous membrane tissue or blood vessel.
According to one embodiment of the invention, the compsn of treatment anaphylactic disease comprises lactobacillus paracasei strain GMNL-133, and the content of secondary lactobacillus johnsonii strain GMNL-133 can effectively improve anaphylactic disease.
Above-mentioned secondary lactobacillus johnsonii strain GMNL-133 can be viable bacteria or the heat treated dead bacterium of process.The compsn of treatment anaphylactic disease can be oral compsns, for example medical composition or food compsns.
According to another embodiment of the present invention, the compsn of treatment anaphylactic disease can further comprise at least a other bacterial strain.Other bacterial strain is selected from by the lactobacillus acidophilus (Lactobacillus acidophilus); Lactobacillus plantarum (Lactobacillus plantarum); Bifidus longum bb (Bifidobacterium longum); Fermentation lactobacillus (Lactobacillus fermentum); Bulgaricus ccm (Lactobacillus bulgaricus); Thermophilus streptococcus (Streptococcus thermophilus); Cheese lactobacillus spp (Lactobacillus cremors); Rhamnose lactic acid bacteria (Lactobacillus rhamnosus); The group that lactobacillus reuteri (Lactobacillus reuteri) and above-mentioned arbitrary combination are formed.Generally speaking, the bacterium of other bacterial strain amount can be about 1 * 10
7CFU/g or more than.
The separation of embodiment 1, bacterial strain, screening and evaluation
The inventor separates over one hundred strain lactobacillus spp from a healthy human body gi tract corpse or other object for laboratory examination and chemical testing, and sets up a strain isolated strain library.Has the lactobacillus spp that slows down the irritated relative disease potentiality of treatment for searching; Respectively with each lactobacillus spp in the strain library and mouse spleen co-culture of cells; Carry out mouse spleen cell IFN-γ secretion quantitative analysis, and then therefrom filter out strain isolated GMNL-133 and one can stimulate the lactobacillus spp of a large amount of IFN-γ of mouse spleen emiocytosis.
This strain isolated GMNL-133 is carried out the analysis of each item strain identification.Fig. 1 is the aspect graph of strain isolated GMNL-133 in microscopically.Strain isolated GMNL-133 Preliminary experiment results is shown as Gram-positive bacillus, does not have catalase, oxydase and a mobility, under aerobic and anaerobic environment, all can grow.
Further analyze again with 16S rDNA sequence and API 50 CHL identification systems.The 16S rDNA partial sequence of strain isolated GMNL-133 is shown in SEQ ID No:1.Table one is the result that strain isolated GMNL-133 analyzes with the API50CHL identification systems.
The analytical results of the API 50CHL identification systems of table one strain isolated GMNL-133
-: negative reaction; +: positive reaction; W: faint positive reaction
Comprehensive above-mentioned qualification result shows that strain isolated GMNL-133 is secondary lactobacillus johnsonii.
The variance analysis of the secondary lactobacillus johnsonii of embodiment 2, secondary lactobacillus johnsonii strain GMNL-133 and other commercially available prod
With secondary lactobacillus johnsonii strain GMNL-133 and commercially available yoghourt (for example unified LP33 sour milk; Include secondary lactobacillus johnsonii strain LP33), yogurt (the for example Japanese kylin adult's of company vigour yogurt; Include secondary lactobacillus johnsonii strain KW3110), probiotic bacterium protective foods (the quick probiotic bacterium of hundred bright living skill prestige for example; Include secondary lactobacillus johnsonii strain BRAP-01) etc. the bacterial strain that contains in the product of secondary lactobacillus johnsonii carry out variance analysis, comprise the analyses of randomly amplified polymorphic DNA (RAPD) electrophoretic analysis and API 50CHL identification systems.
It is that the primer of 5 '-CCGCGACGTT-3 ' (SEQ ID No:2) carries out the polymerase chain reaction that the RAPD electrophoretic analysis utilizes sequence, to analyze the difference between the secondary lactobacillus johnsonii strain randomly amplified polymorphic DNA in secondary lactobacillus johnsonii strain GMNL-133 and the commercially available prod.The polymerase chain reaction condition is 93 ℃, 10 minutes, the double-stranded DNA sex change is separated into strand.Then carry out following circulation 35 times: 93 ℃, 1 minute; 36 ℃, 1 minute; 74 ℃, 1 minute.Carry out coming in 5 minutes amplification of DNA fragments with 74 ℃ at last.Reaction is carried out the DNA electrophoretic analysis with 1.5% agarose after accomplishing.
Fig. 2 is the RAPD electrophorogram of secondary lactobacillus johnsonii strain in secondary lactobacillus johnsonii strain GMNL-133 and other commercially available prod.Wherein swimming lane M is the molecular weight sign, and swimming lane 1 to 4 is respectively the RAPD collection of illustrative plates of LP33, KW3110, GMNL-133 and BRAP-01.Can know that by Fig. 2 result the RAPD collection of illustrative plates of GMNL-133 and KW3110, LP33, BRAP-01 is neither together.
The result that the API 50CHL identification systems of the secondary lactobacillus johnsonii strain of secondary bar buttermilk acidfast bacilli strain GMNL-133 and other commercially available prod are analyzed is shown in table two.
The result that the API identification systems of the secondary lactobacillus johnsonii strain of table second mate bar buttermilk acidfast bacilli strain GMNL-133 and other commercially available prod are analyzed
-: negative reaction; +: positive reaction; W: faint positive reaction
Can know that by table two secondary lactobacillus johnsonii strain GMNL-133, LP33 are neither identical with the biochemical reaction of BRAP-01.Wherein, secondary lactobacillus johnsonii strain GMNL-133 is different fully to the biochemical reaction that L-sorbose, methyl-α D-glucoside, amygdaloside and D-contain melizitose with LP33.It is different fully that secondary lactobacillus johnsonii strain GMNL-133 and BRAP-01 then contain the biochemical reaction of melizitose, D-turanose, D-lyxose, D-tagatose and glucono-for L-arabinose, D-ribose, methyl D-xyloside, L-rhamnosyl, inositol, D-Sorbitol Powder, D-lactose, D-melibiose, synanthrin, D-.
Can know that in sum secondary lactobacillus johnsonii strain GMNL-133, KW3110, LP33 are neither identical in gene order and biochemical reaction with BRAP-01; The secondary lactobacillus johnsonii strain of four strains is different bacterial strains really, confirms that secondary lactobacillus johnsonii strain GMNL-133 of the present invention is a novel strain.
Respectively with the secondary lactobacillus johnsonii strain in secondary lactobacillus johnsonii strain GMNL-133 and the aforementioned various commercially available prod, KW3110, LP33 and BRAP-01, after the spleen cell co-cultivation of normal mouse, the IFN-γ secretory volume of mouse spleen cell relatively.
With RPMI 1640 substratum (GIBCO/BRL
Gaithersburg that contains 10% foetal calf serum; MD USA) cultivates the spleen cell of taking from BALB/c mouse.With 4x10
5Individual mouse spleen cell is added in 96 orifice plates, and adds 10 respectively
6Above-mentioned each lactic bacilli strains, in 37 ℃, the environment that contains 5% carbonic acid gas was cultivated 48 hours down.Afterwards; With cell culture supernatant with commercially available ELISA test kit (OptEIA Mouse IFN-γ Set; BD Biosciences Pharmingen
San Diego; CA, USA) mensuration IFN-γ content wherein.
The IFN-γ secretory volume that Fig. 3 stimulates the mouse spleen cell to produce respectively for secondary lactobacillus johnsonii strain in secondary lactobacillus johnsonii strain GMNL-133 and other commercially available prod.Can know by Fig. 3 result; Secondary lactobacillus johnsonii strain GMNL-133 can stimulate a large amount of IFN-γ secretions to produce; And secretory volume is about more than at least 3 times of lactobacillus paracasei strain in other commercially available prod, shows that secondary lactobacillus johnsonii strain GMNL-133 of the present invention has preferable effect than other lactobacillus paracasei strain for treatment allergy.
The mouse of sensitized mice pattern is the female BALB/c mouse available from Taiwan Le Sike biotechnology.Raise in the Animal House of control light and temperature.BALB/c mouse was entered the room after a week, treated that animal begins test after stable.
Mouse is divided into normal group, experimental group and placebo to experimentize.Experimental group and placebo mouse promptly utilized the Protalbinic acid (ovalbumin of abdominal injection 50 μ g respectively on the 0th day in the experiment beginning; OVA) with aluminium glue adjuvant (the aluminum hydroxide adjuvant of 4mg; Alum) to the mouse body; And in experiment the 14th and 28 day the time, again with the alum duplicate injection mouse of OVA and the 4mg of 25 μ g.
During experiment was carried out, beginning from the 1st day was feeding normal group and 0.5 milliliter of RO water of placebo mouse every day, and experimental mice is feeding 2x10 then
7Lactobacillus paracasei strain GMNL-133 viable bacteria.Experiment was carried out 35 days altogether, in the 35th day mouse was put to death, and before putting to death, was taken a blood sample by mousetail, isolated serum and supplied follow-up IgE of carrying out and IgG2a to analyze.
Each is organized BALB/c mouse with CO
2After smoothing method is put to death, place mikrobe to use petridish the spleen taking-up, add 6ml PBS, the spleen squeezing mill is broken to the suspension-s state with glass stick with aseptic technique.Absorption suspension-s slowly adds the Ficoll-Hypaque that has installed 6ml in advance, and ((720g, 20min), throw out is a red blood corpuscle so that spleen cell is separated to carry out gradient centrifugation for 17-1400-02,15ml centrifuge tube Pharmacia).Evaluate oneself and take out spleen cell at the interface, behind PBS cleaning secondary, cell concn is adjusted into 4 * 10 with the RPMI-1640 substratum
6Cell/ml injects 96 orifice plates with spleen cell with each hole 100 μ l.
Spleen cell is got supernatant in adding after OVA (cultivating concentration 30 μ g/mL) cultivates 48 hours, detects the concentration of TGF-β, IFN-γ, IL-10 and IL-17 with the ELISA mode.
Fig. 4 A to 4B is respectively in the sensitized mice pattern experiment, and IgE and IgG2a expression amount are with the standardized column diagram of the expression amount of placebo in serum of each group, and the * mark representes to compare with placebo the significant difference (p＜0.05) that has on the statistics.Can know that by Fig. 4 A to 4B result the OVA specific IgE in the BALB/c mouse serum of experimental group (feeding lactobacillus paracasei strain GMNL-133) has been compared significant decline with placebo.Yet, OVA specific IgG 2a in the BALB/c mouse serum of experimental group (feeding lactobacillus paracasei strain GMNL-133), comparing with placebo is significant increase.Point out that according to document IgG2a antibody is secreted by the Th1 cell.Therefore, the secondary lactobacillus johnsonii strain of feeding GMNL-133 can make the Th1 cell activation of BALB/c mouse, and then reduces the generation of OVA specific IgE in the serum.
Fig. 5 A to 5D then is respectively in the experiment of sensitized mice pattern; TGF-β, IFN-γ, IL-10 and IL-17 expression amount in spleen cell nutrient solution of each group are with the standardized column diagram of the expression amount of placebo, and wherein the * mark representes to compare with placebo the significant difference (p＜0.05) that has on the statistics.Can be known that by Fig. 5 A to 5D result the experimental group behind the feeding lactobacillus paracasei strain GMNL-133 is compared with placebo, the TGF-β in the spleen cell nutrient solution of experimental group, IFN-γ, IL-10 and IL-17 concentration all have significant increase.
Many anaphylactic diseases are because the immunoreation imbalance between Th1 cell and the Th2 cell, and the reaction of sensibiligen are partial to due to the immunoreation of Th2 cell.And have document to point out, and through improving the immune balance of Th1/Th2, the Th2 cell response is turned to the Th1 immunoreation, can slow down anaphylactic disease.When the immunization route of Th1 cell was partial in immunoreation, Th1 cell meeting secretion of gamma-IFN helped IgG2a production of antibodies, activated macrophage, natural killer cell line and poisoning type T cell, strengthens cell immune response.In addition, the Th17 cell can be secreted IL-17, can be used as the bridge of regulating between congenital immunity and the Acquired immunity, that is to say that the Th17 cell is the hub site of between cellular immunization and humoral immunization, regulating.
Moreover another group adjustment type T cell can reach the generation that suppresses anaphylactic disease through the immunoreation that suppresses the Th2 cell.The characteristic of adjustment type T cell is to secrete IL-10 or TGF-β, and then suppresses the activation and the hyperplasia of target cell.
In sum, secondary lactobacillus johnsonii strain GMNL-133 of the present invention can stimulate the Th-17 cell of vivo immuning system, and then makes the immunoreation of Th1/Th2 transfer the Th1 approach to.Moreover secondary lactobacillus johnsonii strain GMNL-133 of the present invention also can stimulate adjustment type T cell, and then suppresses the immunoreation of Th2 cell, reaches and slows down anaphylaxis.
Embodiment 5, secondary lactobacillus johnsonii strain GMNL-133 are for the effect assessment that improves of tool atopic dermatitis mouse
To raise in the Animal House of control light and temperature available from the big normal male BALB/c mouse of 6 weeks of Taiwan Le Sike biotechnology.BALB/c mouse was entered the room after a week, treated that animal begins test after stable.
Mouse is divided into normal group, experimental group and placebo to experimentize.Experimental group and placebo mouse are respectively when experiment begins the 0th day; It is inboard that 0.3% 3 nitre chlorobenzene solution of 10 microlitres is coated the BALB/c mouse auris dextra; Afterwards during experiment is carried out; Inferior to three nitre chlorobenzene solutions of same area coating same dose, produce atopic dermatitis on every Wendesdays, form atopic dermatitis mouse pattern to bring out mouse.Simultaneously, during experiment was carried out, beginning from the 1st day was feeding normal group and 0.5 milliliter of RO water of placebo mouse every day, and experimental mice is feeding 2x10 then
7Lactobacillus paracasei strain GMNL-133 viable bacteria.
Experiment was carried out 21 days altogether.In the 22nd day mouse is put to death, and before putting to death, measure mouse right ear thickness, gather mouse ear tissue and, isolate serum confession in the future carrying out Tegeline analysis by the mousetail blood sampling with thickness piece.Mouse ear tissue places the 50mM phosphate buffer solution that contains proteinase inhibitor, after homogenizing, with 18870g gravity centrifugal 30 minutes, gets supernatant is measured tumor necrosis factor TNF-alpha in the supernatant with enzymoimmunoassay content.
Fig. 6 A figure is that each organizes the column diagram of mouse right ear thickness results in the experiment of atopic dermatitis mouse pattern.Fig. 6 B to 6C is respectively in the atopic dermatitis mouse pattern experiment, and each organizes IgE and IgG1 expression amount in the mice serum with the standardized column diagram of the expression amount of placebo.Fig. 6 D figure is in the experiment of atopic dermatitis mouse pattern, and each organizes the expression amount of the TNF-α in the mouse ear tissue with the standardized column diagram of the expression amount of placebo.The result of Fig. 6 B to Fig. 6 D representes that mode is is 100% with the measured content of placebo, the measured content of normal group and experimental group respectively with placebo relatively, the * mark representes to compare with placebo the significant difference (p＜0.05) that has on the statistics.
Result according to Fig. 6 A to 6D; Be presented under the atopic dermatitis mouse pattern; The TNF-α secretory volume of IgE, IgG1 and ear's tissue in its ear thickness of mouse of feeding lactobacillus paracasei strain GMNL-133 viable bacteria (experimental group), the serum; With the not mouse comparison of feeding lactobacillus paracasei strain GMNL-133 viable bacteria (placebo), remarkable decline is arranged all.Therefore, lactobacillus paracasei strain GMNL-133 bacterial strain of the present invention can obviously improve the symptom of atopic dermatitis, and is also inhibited for the intravital anaphylaxis of biology.
Claims (10)
1. separated secondary lactobacillus johnsonii strain GMNL-133, it is preserved in Chinese typical culture collection center (CCTCC), and deposit number is CCTCC M 2011311.
2. according to the purposes of the secondary lactobacillus johnsonii strain GMNL-133 of claim 1, be used to make the compsn of treatment atopic dermatitis.
3. according to the purposes of the secondary lactobacillus johnsonii strain GMNL-133 of claim 1, be used to make the compsn of treatment anaphylactic disease.
4. according to claim 2 or 3 described purposes, should pair lactobacillus johnsonii strain GMNL-133 be viable bacteria wherein.
5. according to claim 2 or 3 described purposes, wherein said composition is a medical composition or a food compsns.
6. a compsn that is used to treat atopic dermatitis comprises the secondary lactobacillus johnsonii strain GMNL-133 according to claim 1, and content that should pair lactobacillus johnsonii strain GMNL-133 can effectively improve atopic dermatitis.
7. a compsn that is used to treat allergic symptom comprises the secondary lactobacillus johnsonii strain GMNL-133 according to claim 1, and content that should pair lactobacillus johnsonii strain GMNL-133 can effectively improve anaphylactic disease.
8. according to claim 6 or 7 described compsns, should pair lactobacillus johnsonii strain GMNL-133 be viable bacteria wherein.
9. according to claim 6 or 7 described compsns, wherein said composition is a medical composition or a food compsns.
10. according to claim 6 or 7 described compsns, further comprise:
At least a other bacterial strain, this other bacterial strain are selected from a group that is made up of lactobacillus acidophilus (Lactobacillus acidophilus), lactobacillus plantarum (Lactobacillus plantarum), bifidus longum bb (Bifidobacterium longum), fermentation lactobacillus (Lactobacillus fermentum), bulgaricus ccm (Lactobacillus bulgaricus), thermophilus streptococcus (Streptococcus thermophilus), cheese lactobacillus spp (Lactobacillus cremors), rhamnose lactic acid bacteria (Lactobacillus rhamnosus), lactobacillus reuteri (Lactobacillus reuteri) and above-mentioned arbitrary combination.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110319407.7A CN102399718B (en) | 2011-10-14 | 2011-10-14 | Secondary Lactobacillus casei strain GMNL 133, composition for improving Atopic dermatitis or other anaphylactic diseases and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110319407.7A CN102399718B (en) | 2011-10-14 | 2011-10-14 | Secondary Lactobacillus casei strain GMNL 133, composition for improving Atopic dermatitis or other anaphylactic diseases and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102399718A true CN102399718A (en) | 2012-04-04 |
| CN102399718B CN102399718B (en) | 2017-07-07 |
Family
ID=45882373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110319407.7A Active CN102399718B (en) | 2011-10-14 | 2011-10-14 | Secondary Lactobacillus casei strain GMNL 133, composition for improving Atopic dermatitis or other anaphylactic diseases and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102399718B (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107114794A (en) * | 2017-06-06 | 2017-09-01 | 上海真合生物技术有限公司 | Probiotic composition for strengthening antiallergy ability |
| CN107916236A (en) * | 2016-10-05 | 2018-04-17 | 益福生医股份有限公司 | Lactobacillus paracasei subspecies paracasei K56 |
| CN108707557A (en) * | 2018-03-23 | 2018-10-26 | 景岳生物科技股份有限公司 | Prevent, improve or slow down probiotic composition and its application of cancer of pancreas |
| CN110013490A (en) * | 2018-01-09 | 2019-07-16 | 柯顺议 | Probiotic composition and application thereof |
| CN110151672A (en) * | 2018-02-12 | 2019-08-23 | 景岳生物科技股份有限公司 | A kind of lactobacillus plantarum GMNL-6 composition is used for the purposes of skin care |
| CN110892914A (en) * | 2019-11-20 | 2020-03-20 | 内蒙古伊利实业集团股份有限公司 | New application of lactobacillus paracasei K56 in improvement of asthma and related allergic symptoms |
| CN111565582A (en) * | 2018-04-25 | 2020-08-21 | 曾根农场股份公司 | Composition for type I allergy |
| CN112940968A (en) * | 2021-02-07 | 2021-06-11 | 山东凤凰生物有限公司 | Lactobacillus fermentum, lactobacillus fermentum culture and preparation method thereof |
| CN113473997A (en) * | 2018-10-26 | 2021-10-01 | Lac2生物群系有限公司 | Bacterial strains of the species lactobacillus paracasei for oral or topical application in the treatment of female urogenital disorders |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5556785A (en) * | 1992-11-24 | 1996-09-17 | Institut Pasteur De Kyoto | Lactobacillus used to enhance immunological functions |
| CN1498627A (en) * | 2002-11-06 | 2004-05-26 | 景岳生物科技股份有限公司 | New usage of strain of lactobacillus for curing irritability |
| TW200532018A (en) * | 2004-03-25 | 2005-10-01 | Genmont Biotech Inc | Novel microorganism strain gmnl-32 of lactobacillus paracasei and its use for treating allergy related diseases |
| CN101575582A (en) * | 2008-05-08 | 2009-11-11 | 景岳生物科技股份有限公司 | Lactobacillus separation strains with anti-inflammatory activity and application thereof |
-
2011
- 2011-10-14 CN CN201110319407.7A patent/CN102399718B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5556785A (en) * | 1992-11-24 | 1996-09-17 | Institut Pasteur De Kyoto | Lactobacillus used to enhance immunological functions |
| CN1498627A (en) * | 2002-11-06 | 2004-05-26 | 景岳生物科技股份有限公司 | New usage of strain of lactobacillus for curing irritability |
| TW200532018A (en) * | 2004-03-25 | 2005-10-01 | Genmont Biotech Inc | Novel microorganism strain gmnl-32 of lactobacillus paracasei and its use for treating allergy related diseases |
| CN101575582A (en) * | 2008-05-08 | 2009-11-11 | 景岳生物科技股份有限公司 | Lactobacillus separation strains with anti-inflammatory activity and application thereof |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107916236A (en) * | 2016-10-05 | 2018-04-17 | 益福生医股份有限公司 | Lactobacillus paracasei subspecies paracasei K56 |
| CN107114794A (en) * | 2017-06-06 | 2017-09-01 | 上海真合生物技术有限公司 | Probiotic composition for strengthening antiallergy ability |
| CN110013490A (en) * | 2018-01-09 | 2019-07-16 | 柯顺议 | Probiotic composition and application thereof |
| CN110151672A (en) * | 2018-02-12 | 2019-08-23 | 景岳生物科技股份有限公司 | A kind of lactobacillus plantarum GMNL-6 composition is used for the purposes of skin care |
| CN108707557A (en) * | 2018-03-23 | 2018-10-26 | 景岳生物科技股份有限公司 | Prevent, improve or slow down probiotic composition and its application of cancer of pancreas |
| CN108707557B (en) * | 2018-03-23 | 2021-04-16 | 景岳生物科技股份有限公司 | Probiotic composition for preventing, improving or slowing pancreatic cancer and application thereof |
| CN111565582A (en) * | 2018-04-25 | 2020-08-21 | 曾根农场股份公司 | Composition for type I allergy |
| CN113473997A (en) * | 2018-10-26 | 2021-10-01 | Lac2生物群系有限公司 | Bacterial strains of the species lactobacillus paracasei for oral or topical application in the treatment of female urogenital disorders |
| CN110892914A (en) * | 2019-11-20 | 2020-03-20 | 内蒙古伊利实业集团股份有限公司 | New application of lactobacillus paracasei K56 in improvement of asthma and related allergic symptoms |
| CN112940968A (en) * | 2021-02-07 | 2021-06-11 | 山东凤凰生物有限公司 | Lactobacillus fermentum, lactobacillus fermentum culture and preparation method thereof |
| CN112940968B (en) * | 2021-02-07 | 2022-07-01 | 山东凤凰生物科技股份有限公司 | Lactobacillus fermentum, lactobacillus fermentum culture and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102399718B (en) | 2017-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102399718A (en) | Strain of Lactobacillus paracasei GMNL-133 and composition for improving atopic dermatitis or other allergic diseases and purpose thereof | |
| JP4740999B2 (en) | Selection and use of lactic acid bacteria to reduce inflammation in mammals | |
| Hong et al. | Effects of kefir supernatant and lactic acid bacteria isolated from kefir grain on cytokine production by macrophage | |
| Yang et al. | Oral administration of live Bifidobacterium substrains isolated from healthy centenarians enhanced immune function in BALB/c mice | |
| KR101504373B1 (en) | Lactobacillus paracasei strain lt12 as immunity regulatory agent | |
| CN101328468B (en) | Antiallergic lactic acid bacteria | |
| Tuo et al. | Study of probiotic potential of four wild Lactobacillus rhamnosus strains | |
| US11667977B2 (en) | Method of using a medication or a food supplement with lactobacillus strains isolated from kimere for strengthining the immune system | |
| EP2581461B1 (en) | Composition and use of lactobacillus paracasei strain GMNL-133 in treating atopic dermatitis or other allergic diseases | |
| CN109182162B (en) | Lactobacillus plantarum with antioxidant capacity and application thereof | |
| Domingos-Lopes et al. | Immunomodulatory activity of exopolysaccharide producing Leuconostoc citreum strain isolated from Pico cheese | |
| CN103649304A (en) | Isolated microorganism strains lactobacillus plantarum MCC2 DSM 23881 and lactobacillus gasseri MCC2 DSM 23882 and their use | |
| CN107114794A (en) | Probiotic composition for strengthening antiallergy ability | |
| CN103550258B (en) | The purposes of lactobacillus strain immunity moderation reaction | |
| TWI398259B (en) | Composition and use of lactobacillus paracasei strain gmnl-133 in treating atopic dermatitis or other allergic diseases | |
| JP7358001B2 (en) | Lactic acid bacteria, interleukin-22 production inducer, skin barrier function enhancer | |
| Lin et al. | Induced apoptosis of Th2 lymphocytes and inhibition of airway hyperresponsiveness and inflammation by combined lactic acid bacteria treatment | |
| KR20130049554A (en) | Composition for preventing or treating atopic dermatitis | |
| CN102028224B (en) | Antiallergic lactobacillus | |
| TWI429444B (en) | Novel lactobacillus strains and their uses for modulating immune response | |
| US8753624B2 (en) | Composition and use of Lactobacillus paracasei strain GMNL-133 in treating atopic dermatitis or other allergic diseases | |
| CN103224895B (en) | Novel lactobacillus lodelbrueckii strain and application thereof in improving autoimmune diseases | |
| TW201106957A (en) | The new strain of Lactobacillus plantarum LP28 and its use in treating allergy | |
| JP2015130842A (en) | SCREENING METHOD OF ORAL IMMUNOLOGICAL TOLERANCE SUBSTANCE AIMING INDUCTION OF Foxp3 POSITIVE CONTROL T-CELL AND IFN-γ PRODUCING IL-10 PRODUCING T-CELL AS INDEX AND ORAL IMMUNOLOGICAL TOLERANCE ENHANCING COMPOSITION | |
| CN102657260B (en) | Antiallergic lactobacillus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |